-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Financial Review: Dyne Therapeutics (NASDAQ:DYN) & Galectin Therapeutics (NASDAQ:GALT)
Financial Review: Dyne Therapeutics (NASDAQ:DYN) & Galectin Therapeutics (NASDAQ:GALT)
Galectin Therapeutics (NASDAQ:GALT – Get Rating) and Dyne Therapeutics (NASDAQ:DYN – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.
Profitability
This table compares Galectin Therapeutics and Dyne Therapeutics' net margins, return on equity and return on assets.
Get Galectin Therapeutics alerts:Net Margins | Return on Equity | Return on Assets | |
Galectin Therapeutics | N/A | -1,003.71% | -102.64% |
Dyne Therapeutics | N/A | -51.86% | -44.99% |
Analyst Ratings
This is a summary of recent ratings for Galectin Therapeutics and Dyne Therapeutics, as reported by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Galectin Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
Dyne Therapeutics | 0 | 0 | 4 | 0 | 3.00 |
Volatility & Risk
Galectin Therapeutics has a beta of 1.91, indicating that its share price is 91% more volatile than the S&P 500. Comparatively, Dyne Therapeutics has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500.
Earnings & Valuation
This table compares Galectin Therapeutics and Dyne Therapeutics' top-line revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Galectin Therapeutics | N/A | N/A | -$30.53 million | ($0.59) | -2.98 |
Dyne Therapeutics | N/A | N/A | -$149.29 million | ($3.53) | -3.96 |
Dyne Therapeutics is trading at a lower price-to-earnings ratio than Galectin Therapeutics, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
11.9% of Galectin Therapeutics shares are owned by institutional investors. Comparatively, 90.2% of Dyne Therapeutics shares are owned by institutional investors. 39.4% of Galectin Therapeutics shares are owned by insiders. Comparatively, 42.3% of Dyne Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
About Galectin Therapeutics
(Get Rating)
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
About Dyne Therapeutics
(Get Rating)
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Galectin Therapeutics (NASDAQ:GALT – Get Rating) and Dyne Therapeutics (NASDAQ:DYN – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.
纳斯达克:GALT-GET评级公司和戴恩治疗公司(纳斯达克:DYN-GET评级)都是小盘股医疗公司,但哪只股票更优?我们将根据两家公司的盈利能力、估值、收益、分析师建议、股息、机构所有权和风险等方面的实力进行比较。
Profitability
盈利能力
This table compares Galectin Therapeutics and Dyne Therapeutics' net margins, return on equity and return on assets.
该表比较了Galectin治疗公司和Dye治疗公司的净利润率、股本回报率和资产回报率。
Net Margins | Return on Equity | Return on Assets | |
Galectin Therapeutics | N/A | -1,003.71% | -102.64% |
Dyne Therapeutics | N/A | -51.86% | -44.99% |
净利润率 | 股本回报率 | 资产回报率 | |
Galectin治疗药物 | 不适用 | -1,003.71% | -102.64% |
戴恩治疗公司 | 不适用 | -51.86% | -44.99% |
Analyst Ratings
分析师评级
This is a summary of recent ratings for Galectin Therapeutics and Dyne Therapeutics, as reported by MarketBeat.com.
这是MarketBeat.com报道的Galectin治疗公司和Dye治疗公司最近的评级摘要。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Galectin Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
Dyne Therapeutics | 0 | 0 | 4 | 0 | 3.00 |
销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
Galectin治疗药物 | 0 | 0 | 1 | 0 | 3.00 |
戴恩治疗公司 | 0 | 0 | 4 | 0 | 3.00 |
Volatility & Risk
波动性与风险
Galectin Therapeutics has a beta of 1.91, indicating that its share price is 91% more volatile than the S&P 500. Comparatively, Dyne Therapeutics has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500.
Galectin Treeutics的贝塔系数为1.91,这表明其股价的波动性比标准普尔500指数高出91%。相比之下,戴恩治疗公司的贝塔系数为0.7,这表明其股价的波动性比标准普尔500指数低30%。
Earnings & Valuation
收益与估值
This table compares Galectin Therapeutics and Dyne Therapeutics' top-line revenue, earnings per share and valuation.
此表比较了Galectin治疗公司和Dye治疗公司的营收、每股收益和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Galectin Therapeutics | N/A | N/A | -$30.53 million | ($0.59) | -2.98 |
Dyne Therapeutics | N/A | N/A | -$149.29 million | ($3.53) | -3.96 |
总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
Galectin治疗药物 | 不适用 | 不适用 | -3,053万元 | ($0.59) | -2.98 |
戴恩治疗公司 | 不适用 | 不适用 | -1.4929亿美元 | ($3.53) | -3.96 |
Dyne Therapeutics is trading at a lower price-to-earnings ratio than Galectin Therapeutics, indicating that it is currently the more affordable of the two stocks.
戴恩治疗公司的市盈率低于Galectin治疗公司,这表明它目前是两只股票中更负担得起的一只。
Institutional & Insider Ownership
机构与内部人持股
11.9% of Galectin Therapeutics shares are owned by institutional investors. Comparatively, 90.2% of Dyne Therapeutics shares are owned by institutional investors. 39.4% of Galectin Therapeutics shares are owned by insiders. Comparatively, 42.3% of Dyne Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Galectin治疗公司11.9%的股份由机构投资者持有。相比之下,戴恩治疗公司90.2%的股份由机构投资者持有。Galectin治疗公司39.4%的股份由内部人士持有。相比之下,戴恩治疗公司42.3%的股份由内部人士持有。强大的机构持股表明,捐赠基金、对冲基金和大型基金管理公司相信,一家公司的长期表现将好于大盘。
About Galectin Therapeutics
关于Galectin Treateutics
(Get Rating)
(获取评级)
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Galectin治疗公司是一家临床阶段的生物制药公司,致力于研究和开发治疗纤维化、癌症和其他疾病的药物。该公司的主要候选产品是belapectin(GR-MD-02)Galectin-3抑制剂,这是一种半乳阿拉伯酸鼠李半乳糖醛酸葡聚糖聚合物,处于第三阶段临床试验,用于治疗与脂肪性肝病和非酒精性脂肪性肝炎肝硬化相关的肝纤维化,以及治疗癌症。该公司还致力于开发用于治疗心脏和血管纤维化的GM-CT-01,该药处于临床前开发阶段,并专注于开发用于治疗牛皮癣以及肺和肾纤维化的贝拉菌素。该公司通过其Galectin Sciences,LLC,这是一家由SBH Sciences,Inc.共同拥有的合作合资企业,研究和开发口服用Galectin-3的小有机分子抑制剂。该公司前身为Pro-PharmPharmticals,Inc.,并于2011年5月更名为Galectin治疗公司。Galectin治疗公司成立于2000年,总部设在佐治亚州诺克罗斯。
About Dyne Therapeutics
戴恩治疗公司简介
(Get Rating)
(获取评级)
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
戴恩治疗公司是一家肌肉疾病公司,是一家生物技术公司,专注于在美国推进遗传性肌肉疾病的治疗。它利用其提供疾病修正疗法的FORCE平台,为强直性肌营养不良1型、Duchenne肌营养不良和面肩肩关节营养不良以及罕见的骨骼肌、心脏和代谢性肌肉疾病开发各种计划。该公司成立于2017年,总部位于马萨诸塞州沃尔瑟姆。
Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Galectin治疗日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Galectin治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧